Skip to main content
Log in

Three-year experience of catheter-based micro-axial left ventricular assist device, Impella, in Japanese patients: the first interim analysis of Japan registry for percutaneous ventricular assist device (J-PVAD)

  • Original Article
  • Artificial Heart (Clinical)
  • Published:
Journal of Artificial Organs Aims and scope Submit manuscript


Catheter-based micro-axial ventricular assist device Impella® (Abiomed, Danvers, MA) has been used in Japanese patients with drug-refractory acute heart failure (AHF) since 2017. This is the first interim analysis of the ongoing Japan Registry for Percutaneous Ventricular Assist Device (J-PVAD) to investigate the safety and efficacy of Impella support. Between October 2017 and January 2020, 823 Japanese patients, who were treated with the Impella 2.5, CP, or 5.0 pump, were enrolled. The primary endpoints were safety profiles and cumulative 30-day survival. Among them, 44.8% of patients were acute myocardial infarction with cardiogenic shock. The Impella pumps were unable to implant in 4 patients. The Impella 2.5, CP, and 5.0 pumps were used in 72.4%, 6.2%, and 16.6%, respectively, and mean support duration was 8.1 ± 10.2 days. Combination use of Impella and venoarterial extracorporeal membrane oxygenation (VA-ECMO) was applied for 387 patients (47.3%). Pump stop occurred 22 patients (2.7%). Major adverse events included hemolysis (11.2%), hemorrhage/hematoma (6.1%), peripheral ischemia (1.6%), and stroke (1.6%). The overall 30-day survival was 62.2%. Survival of patients with single Impella support was significantly higher than patients with Impella combined with VA-ECMO support (81.1% vs 49.6%; p < 0.01), who had lower blood pressure, lower left ventricular ejection fraction, and higher degree of inotropic support. Results suggest that short-term outcome of Impella support for Japanese patients was favorable with acceptable safety profiles.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others


  1. Okura Y, Ramadan MM, Ohno Y, Mitsuma W, Tanaka K, Ito M, Suzuki K, Tanabe N, Kodama M, Aizawa Y. Impending epidemic: future projection of heart failure in Japan to the year 2055. Circ J. 2008;72:489–91.

    Article  PubMed  Google Scholar 

  2. Shiba N, Watanabe J, Shinozaki T, Koseki Y, Sakuma M, Kagaya Y, Shirato K, Investigators C. Analysis of chronic heart failure registry in the Tohoku district: third year follow-up. Circ J. 2004;68:427–34.

    Article  PubMed  Google Scholar 

  3. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3:7–11.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Nagai T, Sundaram V, Rothnie K, Quint JK, Shoaib A, Shiraishi Y, Kohsaka S, Piper S, McDonagh TA, Hardman SMC, Goda A, Mizuno A, Kohno T, Rigby AS, Yoshikawa T, Clark AL, Anzai T, Cleland JGF. Mortality after admission for heart failure in the UK compared with Japan. Open Heart. 2018;5: e000811.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Ueki Y, Mohri M, Matoba T, Tsujita Y, Yamasaki M, Tachibana E, Yonemoto N, Nagao K. Characteristics and predictors of mortality in patients with cardiovascular shock in japan- results from the japanese circulation society cardiovascular shock registry. Circ J. 2016;80:852–9.

    Article  PubMed  Google Scholar 

  6. Shaefi S, O’Gara B, Kociol RD, Joynt K, Mueller A, Nizamuddin J, Mahmood E, Talmor D, Shahul S. Effect of cardiogenic shock hospital volume on mortality in patients with cardiogenic shock. J Am Heart Assoc. 2015;4: e001462.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Thiele H, Zeymer U, Thelemann N, Neumann FJ, Hausleiter J, Abdel-Wahab M, Meyer-Saraei R, Fuernau G, Eitel I, Hambrecht R, Bohm M, Werdan K, Felix SB, Hennersdorf M, Schneider S, Ouarrak T, Desch S, de Waha-Thiele S, Investigators IIT. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction: long-term 6-year outcome of the randomized IABP-shock II trial. Circulation. 2018.

    Article  PubMed  Google Scholar 

  8. Yoshida S, Toda K, Miyagawa S, Yoshikawa Y, Hata H, Torikai K, Shimamura K, Saito S, Kin K, Maeda K, Domae K, Watanabe Y, Matsuura R, Masada K, Hikoso S, Mizote I, Sera F, Nakamoto K, Masawa T, Sakata Y, Kuratani T, Sawa Y. Impella 5.0 as a bridge to implantable left ventricular assist device- first clinical case in Japan. Circ J. 2018;82:2923–4.

    Article  PubMed  Google Scholar 

  9. Lauridsen MD, Rorth R, Lindholm MG, Kjaergaard J, Schmidt M, Moller JE, Hassager C, Torp-Pedersen C, Gislason G, Kober L, Fosbol EL. Trends in first-time hospitalization, management, and short-term mortality in acute myocardial infarction-related cardiogenic shock from 2005 to 2017: A nationwide cohort study. Am Heart J. 2020;229:127–37.

    Article  CAS  PubMed  Google Scholar 

  10. Thiagarajan RR, Barbaro RP, Rycus PT, McMullan DM, Conrad SA, Fortenberry JD, Paden ML, and centers. Extracorporeal life support organization registry international report 2016. ASAIO J. 2017;63:60–7.

    Article  PubMed  Google Scholar 

  11. Pappalardo F, Schulte C, Pieri M, Schrage B, Contri R, Soeffker G, Greco T, Lembo R, Mullerleile K, Colombo A, Sydow K, De Bonis M, Wagner F, Reichenspurner H, Blankenberg S, Zangrillo A, Westermann D. Concomitant implantation of Impella((R)) on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail. 2017;19:404–12.

    Article  PubMed  Google Scholar 

  12. Patel SM, Lipinski J, Al-Kindi SG, Patel T, Saric P, Li J, Nadeem F, Ladas T, Alaiti A, Phillips A, Medalion B, Deo S, Elgudin Y, Costa MA, Osman MN, Attizzani GF, Oliveira GH, Sareyyupoglu B, Bezerra HG. Simultaneous venoarterial extracorporeal membrane oxygenation and percutaneous left ventricular decompression therapy with impella is associated with improved outcomes in refractory cardiogenic shock. ASAIO J. 2019;65:21–8.

    Article  PubMed  Google Scholar 

  13. Nakamura M, Imamura T, Fukui T, Hori M, Ueno Y, Uen H, Kinugawa K. Impact of the angle between aortic and mitral annulus on the occurrence of hemolysis during Impella support. J Artif Organs. 2020;23:207–13.

    Article  PubMed  Google Scholar 

  14. Roberts N, Chandrasekaran U, Das S, Qi Z, Corbett S. Hemolysis associated with Impella heart pump positioning: In vitro hemolysis testing and computational fluid dynamics modeling. Int J Artif Organs. 2020.

    Article  PubMed  Google Scholar 

  15. Flierl U, Tongers J, Berliner D, Sieweke JT, Zauner F, Wingert C, Riehle C, Bauersachs J, Schafer A. Acquired von Willebrand syndrome in cardiogenic shock patients on mechanical circulatory microaxial pump support. PLoS One. 2017;12: e0183193.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Baumann Kreuziger L, Massicotte MP. Mechanical circulatory support: balancing bleeding and clotting in high-risk patients. Hematology Am Soc Hematol Educ Program. 2015;2015:61–8.

    Article  PubMed  Google Scholar 

  17. Massicotte MP, Maul TM, Snyder TA, Baumann KL. Mechanical circulatory support and antithrombotic therapy: looking for the holy grail. ASAIO J. 2017;63:1–4.

    Article  PubMed  Google Scholar 

  18. Toda K, Sawa Y. Intraaortic balloon pumping (IABP) and impella. Kyobu Geka. 2018;71:821–6.

    PubMed  Google Scholar 

Download references


A part of the current study was presented at 84th Annual Scientific Meeting of the Japanese Circulation Society, Late Breaking Session. IRB information: “Catheter-type ventricular assist device registry study”, Graduate School of Medicine/Faculty of Medicine, Osaka University Ethics Committee, Approval #17232


This study was partially funded by Japan Abiomed Post-Market Surveillance Program.

Author information

Authors and Affiliations



Corresponding author

Correspondence to Yoshiki Sawa.

Ethics declarations

Conflict of interest

No conflict interest of authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Toda, K., Ako, J., Hirayama, A. et al. Three-year experience of catheter-based micro-axial left ventricular assist device, Impella, in Japanese patients: the first interim analysis of Japan registry for percutaneous ventricular assist device (J-PVAD). J Artif Organs 26, 17–23 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: